Recruiting studies: Wet Age Related Macular Degeneration Wamd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Phase N/A · 1 location(s) · Guangzhou Jiayin Biotech Ltd · NCT06859515 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg
Phase 3 · 79 location(s) · Adverum Biotechnologies, Inc. · NCT07482176 Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Phase 1 · 7 location(s) · Caregen Co. Ltd. · NCT06132035 Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Phase N/A · 1 location(s) · Beijing Anlong Biopharmaceutical Co., Ltd. · NCT06718816 Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Phase 1/Phase 2 · 1 location(s) · Fujian Haixi Pharmaceuticals Co., Ltd. · NCT07185841 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636 Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul
Phase 3 · 94 location(s) · 4D Molecular Therapeutics · NCT07064759 A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degenera
Phase 1 · 3 location(s) · Youxin Chen · NCT06213038 Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degen
Phase 2 · 4 location(s) · Adverum Biotechnologies, Inc. · NCT07630649 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/Phase 2 · 25 location(s) · 4D Molecular Therapeutics · NCT05197270 Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 9 location(s) · Skyline Therapeutics (US) Inc. · NCT05986864 Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
Phase 3 · 4 location(s) · Parc de Salut Mar · NCT06952452 A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Phase N/A · 10 location(s) · Skyline Therapeutics · NCT06346600

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.